NewslettersHepatic Cell NewsFDA Grants GENFIT’s GNS561 Orphan Drug Designation for the Treatment of CholangiocarcinomaBy Danielle Corrigan - September 16, 20220289GENFIT announced that the US FDA has granted orphan drug designation to GNS5611 (ezurpimtrostat), a novel clinical-stage autophagy/PPT1 inhibitor, for the treatment of cholangiocarcinoma.[GENFIT]Press Release